

Treatment of advanced heart failure - AI

**FineHeart announces the appointment of Sébastien Robitaille as
Chief Financial Officer**

**A seasoned expert to structure FineHeart's key functions
during its scale-up phase**

Bordeaux, France, April 1, 2025 - FineHeart S.A., a clinical-stage medtech company developing breakthrough solutions for cardiology, announces the appointment of Sébastien Robitaille as Chief Financial Officer.

Driven by the challenges of scaling up innovative healthcare companies, Sébastien brings over 25 years of professional experience, primarily in the pharmaceutical and biotechnology industries, with solid expertise in business transformation and financing, including on the Nasdaq.

Sébastien Robitaille joins FineHeart's management team to support the company's growth and strategic development, focusing on the deployment and commercialization of FlowMaker®, a breakthrough fully implantable medical device for the treatment of advanced heart failure, currently in clinical trials. Sébastien's mission will include overseeing all finance and support functions to ensure FineHeart's growth. He will work closely with Hélène Cima, VP of Finance, who has been supporting the company since its inception.

"Sébastien's appointment is an important step in FineHeart's ongoing transformation and ramp up to becoming a leader in cardiovascular disease treatment. His extensive knowledge and international experience in the healthtech industry will be invaluable in driving our sustained expansion. Beyond his financial expertise, Sébastien has demonstrated his ability to structure high-growth companies with a comprehensive and operational vision." commented Arnaud Mascarell, CEO and co-founder of FineHeart

"Joining FineHeart at this crucial stage of its growth is an incredible opportunity," said Sébastien Robitaille. *"I am excited to join a brilliant and dedicated team that has positioned FineHeart at the forefront of medical technology innovation. I look forward to leveraging my expertise in finance and corporate transformation to support the leadership's ambitious vision and establish FineHeart as a key player in the industry."*

Before joining FineHeart, Sébastien Robitaille held strategic roles at DBV Technologies, a French biotech company listed on Euronext and Nasdaq. He successfully led multiple fundraising efforts, securing over \$1 billion, and orchestrated DBV's transformation from a research startup into a company ready to launch a product in Europe and the United States. Previously, he spent 17 years in various roles within Ipsen's Group Finance Department, contributing to the company's transformation following its IPO.

About FlowMaker®

FlowMaker® is the first implantable cardiac output accelerator, designed by French electrophysiologists and rhythmologists. It assists the heart, adapts to the evolution of the pathology, and can be simply removed without critical risk to the patient. Fully intraventricular, it provides physiological support synchronized with the natural heart contractions. It respects natural blood flow and does not require aortic bypass. By operating in synergy with the native cardiac contraction, the FlowMaker® consumes little energy and does not require any percutaneous connection to external batteries. It is recharged via a transcutaneous energy transfer (TET) system, thereby avoiding any risk of infection and significantly improving patients' quality of life. The device is implanted through a minimally invasive procedure on a beating heart, with an average duration of 90 minutes. This procedure is widely practiced by cardiac surgeons and limits any physiological changes. FlowMaker® represents an effective therapeutic alternative for more than 200,000 patients per year suffering from advanced heart failure who cannot benefit from current therapeutic solutions.

About FineHeart - [FineHeart](#)

FineHeart is a Bordeaux-based medical device company at the clinical stage. Its innovative product, FlowMaker®, could treat 200,000 patients with severe heart failure every year. FineHeart is initially targeting the 50,000 most severe patients eligible for cardiac assistance, but not treated by current LVADs. This first potential market is estimated at over US\$5 billion.

FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stéphane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 147 patents in 25 different families. The first two patients have been implanted successfully as part of the European FIH (First In Human) trials. Further European cardiology centers are expected to join the trials shortly, including France.

FineHeart benefits from the support of a wide range of public, private, industrial and independent investors: including the French groups Lauak and Doliam, FineHeart Founders, as well as the investment funds and historical shareholders Aquiti, Broadview Ventures, Galia, Irdi, M Capital, NACO, UI Investment, Verve Ventures. FineHeart is also financed by the European Union (EIC), Bpifrance and the Nouvelle Aquitaine and Région Centre regions.

European
Innovation
Council



RÉGION
Nouvelle-
Aquitaine



Contacts

Media Relations

Annie-Florence Loyer
afloyer@newcap.fr
+33 (0) 6 88 20 3559

FineHeart Communications

James Palmer
james.palmer@fine-heart.com
+33 (0) 7 60 92 77 72

28 Avenue Gustave Eiffel,
Bâtiment C, 33600 Pessac
France